Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Anais Mahone, Michael Enich, Peter Treitler, James Lloyd & Stephen Crystal. (2023) Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers. The American Journal of Drug and Alcohol Abuse 49:5, pages 606-617.
Read now
Read now
Rachel K. Landis, Jonathan S. Levin, Brendan Saloner, Adam J. Gordon, Andrew W. Dick, Tisamarie B. Sherry, Douglas L. Leslie, Mark Sorbero & Bradley D. Stein. (2022) Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine. Substance Abuse 43:1, pages 1057-1071.
Read now
Read now
Walter Ling, Steve Shoptaw & David Goodman-Meza. (2019) Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation. Substance Abuse and Rehabilitation 10, pages 69-78.
Read now
Read now
William S. John & Li-Tzy Wu. (2019) Sex differences in the prevalence and correlates of emergency department utilization among adults with prescription opioid use disorder. Substance Use & Misuse 54:7, pages 1178-1190.
Read now
Read now
Bradley D. Stein, Andrew W. Dick, Mark Sorbero, Adam J. Gordon, Rachel M. Burns, Douglas L. Leslie & Rosalie Liccardo Pacula. (2018) A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees. Substance Abuse 39:4, pages 419-425.
Read now
Read now
Sunil Sirohi & Amit K Tiwari. (2016) Pain in the management of opioid use disorder. Journal of Pain Research 9, pages 963-966.
Read now
Read now
Adam J. Gordon. (2016) Integrating policy and research into addiction practice, AMERSA abstracts, and an appreciation to our reviewers. Substance Abuse 37:2, pages 271-275.
Read now
Read now
Matthew Tierney, Deborah S. Finnell, Madeline A. Naegle, Colleen LaBelle & Adam J. Gordon. (2015) Advanced Practice Nurses: Increasing Access to Opioid Treatment by Expanding the Pool of Qualified Buprenorphine Prescribers. Substance Abuse 36:4, pages 389-392.
Read now
Read now
Articles from other publishers (43)
GERRI R. BAER, RACHANA SINGH & JONATHAN M. DAVIS. 2024. Avery's Diseases of the Newborn. Avery's Diseases of the Newborn
106
122.e6
.
Ashley L. O’Donoghue, Alyse Reichheld, Timothy S. Anderson, Chloe A. Zera, Tenzin Dechen & Jennifer P. Stevens. (2023) Decline in Prenatal Buprenorphine/Naloxone Fills during the COVID-19 Pandemic in the United States. Journal of Addiction Medicine 17:6, pages e399-e402.
Crossref
Crossref
Beth Ann Griffin, Irineo Cabreros, Brendan Saloner, Adam J. Gordon, Rose Kerber & Bradley D. Stein. (2023) Exploring the Association of State Policies and the Trajectories of Buprenorphine Prescriber Patient Caseloads. Substance Abuse.
Crossref
Crossref
Matthew Tierney & Annesa Flentje. (2023) Reducing Drug Overdose Deaths: Significant Changes Needed in U.S. Drug Treatment Policy. Journal of Psychosocial Nursing and Mental Health Services 61:6, pages 7-10.
Crossref
Crossref
Bradley D. Stein, Brendan K. Saloner, Olivia K. Golan, Barbara Andraka-Christou, Christina M. Andrews, Andrew W. Dick, Corey S. Davis, Flora Sheng & Adam J. Gordon. (2023) Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment. JAMA Health Forum 4:5, pages e231102.
Crossref
Crossref
Anneke L. Claypool, Catherine DiGennaro, W. Alton Russell, Melike F. Yildirim, Alan F. Zhang, Zuri Reid, Erin J. Stringfellow, Benjamin Bearnot, Bruce R. Schackman, Keith Humphreys & Mohammad S. Jalali. (2023) Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids. JAMA Health Forum 4:5, pages e231080.
Crossref
Crossref
Edward Y. Liu, Kenneth L. McCall & Brian J. Piper. (2023) Variation in adverse drug events of opioids in the United States. Frontiers in Pharmacology 14.
Crossref
Crossref
Elizabeth A. Suarez, Krista F. HuybrechtsLoreen StraubSonia Hernández-DíazHendrée E. JonesHilary S. ConneryJonathan M. DavisKathryn J. GrayBarry LesterMishka TerplanHelen MogunBrian T. Bateman. (2022) Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy. New England Journal of Medicine 387:22, pages 2033-2044.
Crossref
Crossref
Rachel K. Landis, Isaac Opper, Brendan Saloner, Adam J. Gordon, Douglas L. Leslie, Mark Sorbero & Bradley D. Stein. (2022) Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies. Drug and Alcohol Dependence 241, pages 109669.
Crossref
Crossref
Julia Dickson-Gomez, Sarah Krechel, Antoinette Spector, Margaret Weeks, Jessica Ohlrich, H. Danielle Green Montaque & Jianghong Li. (2022) The effects of opioid policy changes on transitions from prescription opioids to heroin, fentanyl and injection drug use: a qualitative analysis. Substance Abuse Treatment, Prevention, and Policy 17:1.
Crossref
Crossref
Barbara Andraka-Christou, Adam J. Gordon, Kathryn Bouskill, Rosanna Smart, Olivia Randall-Kosich, Matthew Golan, Rachel Totaram & Bradley D. Stein. (2022) Toward a Typology of Office-based Buprenorphine Treatment Laws: Themes From a Review of State Laws. Journal of Addiction Medicine 16:2, pages 192-207.
Crossref
Crossref
Brian King & Andrea Rishworth. (2021) Infectious addictions: Geographies of colliding epidemics. Progress in Human Geography 46:1, pages 139-155.
Crossref
Crossref
Jessica J. Wyse, Benjamin J. Morasco, Jacob Dougherty, Beau Edwards, Devan Kansagara, Adam J. Gordon, P. Todd Korthuis, Anaïs Tuepker, Stephan Lindner, Katherine Mackey, Beth Williams, Anders Herreid-O’Neill, Robin Paynter & Travis I. Lovejoy. (2021) Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence. Drug and Alcohol Dependence 228, pages 108923.
Crossref
Crossref
Victor M. JimenezJr.Jr., Gabriel Castaneda & Charles P. France. (2021) Methocinnamox Reverses and Prevents Fentanyl-Induced Ventilatory Depression in Rats. Journal of Pharmacology and Experimental Therapeutics 377:1, pages 29-38.
Crossref
Crossref
Katherine Mackey, Stephanie Veazie, Johanna Anderson, Donald Bourne & Kim Peterson. (2020) Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review. Journal of General Internal Medicine 35:S3, pages 954-963.
Crossref
Crossref
Laura J. Chavez, Andrea E. Bonny, Katharine A. Bradley, Gwen T. Lapham, Jennifer Cooper, William Miller & Deena J. Chisolm. (2020) Medication Treatment and Health Care Use Among Adolescents With Opioid Use Disorder in Ohio. Journal of Adolescent Health 67:1, pages 33-39.
Crossref
Crossref
Alex K. Gertner, Allison G. Robertson, Hendree Jones, Byron J. Powell, Pam Silberman & Marisa E. Domino. (2020) The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints. Health Services Research 55:3, pages 383-392.
Crossref
Crossref
Bertha K. Madras, N. Jia Ahmad, Jenny Wen & Joshua Sharfstein. (2020) Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers Within the Treatment System. NAM Perspectives.
Crossref
Crossref
Stephanie T. Kha, Judith Scheman, Sara Davin & Edward C. Benzel. (2020) The Impact of Preoperative Chronic Opioid Therapy in Patients Undergoing Decompression Laminectomy of the Lumbar Spine. Spine 45:7, pages 438-443.
Crossref
Crossref
Michelle Knapp & Selena Gilles. (2020) Compassionate Care of the Patient Who Uses Substances. Journal of Infusion Nursing 43:2, pages 70-77.
Crossref
Crossref
Rosanna Smart, Courtney A. Kase, Erin A. Taylor, Susan Lumsden, Scott R. Smith & Bradley D. Stein. (2020) Strengths and weaknesses of existing data sources to support research to address the opioids crisis. Preventive Medicine Reports 17, pages 101015.
Crossref
Crossref
Erick Guerrero, Allison J. Ober, Daniel L. Howard, Tenie Khachikian, Yinfei Kong, Welmoed K. van Deen, Avelardo Valdez, Rebecca Trotzky-Sirr & Michael Menchine. (2020) Organizational factors associated with practitioners’ support for treatment of opioid use disorder in the emergency department. Addictive Behaviors 102, pages 106197.
Crossref
Crossref
Michael D. Mendoza & Holly Ann Russell. 2020. Opioid Therapy in Infants, Children, and Adolescents. Opioid Therapy in Infants, Children, and Adolescents
3
15
.
Charles Marks, Annick Borquez, Sonia Jain, Xiaoying Sun, Steffanie A. Strathdee, Richard S. Garfein, M-J Milloy, Kora DeBeck, Javier A. Cepeda, Dan Werb & Natasha K. Martin. (2019) Opioid agonist treatment scale-up and the initiation of injection drug use: A dynamic modeling analysis. PLOS Medicine 16:11, pages e1002973.
Crossref
Crossref
Alexander C. Tsai, Mathew V. Kiang, Michael L. Barnett, Leo Beletsky, Katherine M. Keyes, Emma E. McGinty, Laramie R. Smith, Steffanie A. Strathdee, Sarah E. Wakeman & Atheendar S. Venkataramani. (2019) Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLOS Medicine 16:11, pages e1002969.
Crossref
Crossref
Corey S. DavisDerek H. CarrElizabeth A. Samuels. (2019) Paraphernalia Laws, Criminalizing Possession and Distribution of Items Used to Consume Illicit Drugs, and Injection-Related Harm. American Journal of Public Health 109:11, pages 1564-1567.
Crossref
Crossref
Evgeny Krupitsky, Elena Blokhina, Edwin Zvartau, Elena Verbitskaya, Dmitri Lioznov, Tatiana Yaroslavtseva, Vladimir Palatkin, Marina Vetrova, Natalia Bushara, Andrei Burakov, Dmitri Masalov, Olga Mamontova, Daniel Langleben, Sabrina Poole, Robert Gross & George Woody. (2019) Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial. The Lancet HIV 6:4, pages e221-e229.
Crossref
Crossref
Stefan G. Kertesz & Adam J. Gordon. (2019) A crisis of opioids and the limits of prescription control: United States. Addiction 114:1, pages 169-180.
Crossref
Crossref
Adam J. Gordon, Gerald Cochran, Marcela C. Smid, Ajay Manhapra & Stefan G. Kertesz. 2019. Treating Opioid Addiction. Treating Opioid Addiction
223
238
.
Barbara Tempalski, Charles M. Cleland, Leslie D. Williams, Hannah L. F. Cooper & Samuel R. Friedman. (2018) Change and variability in drug treatment coverage among people who inject drugs in 90 large metropolitan areas in the USA, 1993–2007. Substance Abuse Treatment, Prevention, and Policy 13:1.
Crossref
Crossref
Stephen A. MartinLisa M. ChiodoJordon D. BosseAmanda Wilson. (2018) The Next Stage of Buprenorphine Care for Opioid Use Disorder. Annals of Internal Medicine 169:9, pages 628.
Crossref
Crossref
Shannon Gwin Mitchell, Jan Gryczynski & Robert P. Schwartz. (2018) Commentary on “The More Things Change: Buprenorphine/Naloxone Diversion Continues While Treatment is Inaccessible”. Journal of Addiction Medicine 12:6, pages 424-425.
Crossref
Crossref
Rebecca L. Haffajee, Amy S.B. Bohnert & Pooja A. Lagisetty. (2018) Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment. American Journal of Preventive Medicine 54:6, pages S230-S242.
Crossref
Crossref
Alana SharpAustin JonesJennifer SherwoodOksana KutsaBrian HonermannGregorio Millett. (2018) Impact of Medicaid Expansion on Access to Opioid Analgesic Medications and Medication-Assisted Treatment. American Journal of Public Health 108:5, pages 642-648.
Crossref
Crossref
Brian J. Piper, Dipam T. Shah, Olapeju M. Simoyan, Kenneth L. McCall & Stephanie D. Nichols. (2018) Trends in Medical Use of Opioids in the U.S., 2006–2016. American Journal of Preventive Medicine 54:5, pages 652-660.
Crossref
Crossref
Peter S. Ostling, Kelly S. Davidson, Best O. Anyama, Erik M. Helander, Melville Q. Wyche & Alan D. Kaye. (2018) America’s Opioid Epidemic: a Comprehensive Review and Look into the Rising Crisis. Current Pain and Headache Reports 22:5.
Crossref
Crossref
Christy K. Scott, Christine E. Grella, Lisa Nicholson & Michael L. Dennis. (2018) Opioid recovery initiation: Pilot test of a peer outreach and modified Recovery Management Checkup intervention for out-of-treatment opioid users. Journal of Substance Abuse Treatment 86, pages 30-35.
Crossref
Crossref
Christopher T. Breen & David A. Fiellin. (2021) Buprenorphine Supply, Access, and Quality: Where We Have Come and the Path Forward. Journal of Law, Medicine & Ethics 46:2, pages 272-278.
Crossref
Crossref
Marcus A. Bachhuber, Pooja K. Mehta, Laura J. Faherty & Brendan Saloner. (2017) Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment. Medical Care 55:12, pages 985-990.
Crossref
Crossref
Cindy Parks Thomas, Erin Doyle, Peter W. Kreiner, Christopher M. Jones, Joel Dubenitz, Alexis Horan & Bradley D. Stein. (2017) Prescribing patterns of buprenorphine waivered physicians. Drug and Alcohol Dependence 181, pages 213-218.
Crossref
Crossref
Anjalee Sharma, Sharon M. Kelly, Shannon Gwin Mitchell, Jan Gryczynski, Kevin E. O’Grady & Robert P. Schwartz. (2017) Update on Barriers to Pharmacotherapy for Opioid Use Disorders. Current Psychiatry Reports 19:6.
Crossref
Crossref
Van Roper & Kim J. Cox. (2017) Opioid Use Disorder in Pregnancy. Journal of Midwifery & Women's Health 62:3, pages 329-340.
Crossref
Crossref
Kelley A. Saia, Davida Schiff, Elisha M. Wachman, Pooja Mehta, Annmarie Vilkins, Michelle Sia, Jordana Price, Tirah Samura, Justin DeAngelis, Clark V. Jackson, Sawyer F. Emmer, Daniel Shaw & Sarah Bagley. (2016) Caring for Pregnant Women with Opioid Use Disorder in the USA: Expanding and Improving Treatment. Current Obstetrics and Gynecology Reports 5:3, pages 257-263.
Crossref
Crossref